Obicetrapib and Cardiovascular Outcomes: A Placebo Controlled, Double Blind, Randomized Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants with Atherosclerotic Cardiovascular Disease (ASCVD) Who are Not Adequately Controlled Despite Maximally Tolerated Lipid Modifying Therapies

Project: Research

Project Details

StatusFinished
Effective start/end date1/07/22 → 30/04/23

Keywords

  • treatment efficacy
  • treatment safety
  • Randomised clinical trial
  • phase 3 study
  • Atherosclerotic Cardiovascular Disease